F. Elahi

Rapid plaque clearance with anti-amyloid therapy for Alzheimer’s disease: in consideration of donanemab treatment duration from real-world cases

ABSTRACT To assess the possibility that individualized duration of donanemab treatment might enable early pausing of therapy, and to explore the possible utility of plasma P-tau217 as a biomarker for treatment response monitoring in real-time, two unrelated patients with early-stage Alzheimer’s disease were treated wit...

Potential contributors to variable penetrance of NOTCH3 p.Arg1231Cys Variant

Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with few treatment options, especially for APOE4/4 homozygotes who carry high genetic risk. Valiltramiprosate/ALZ-801 is an oral small-molecule inhibitor of amyloid-beta oligomer formation in late-stage development as a disease-modifying therapy for A...

CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults

Fibrinogen represents a sensitive marker of BBB leakage, but whether it modifies longitudinal tau progression in cognitively unimpaired (CU) individuals remains unknown.